BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 16712776)

  • 1. A study of the topoisomerase II activity in HIV-1 replication using the ferrocene derivatives as probes.
    Kondapi AK; Satyanarayana N; Saikrishna AD
    Arch Biochem Biophys; 2006 Jun; 450(2):123-32. PubMed ID: 16712776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIalpha and beta--distinct mode of action of two derivatives.
    Sai Krishna AD; Panda G; Kondapi AK
    Arch Biochem Biophys; 2005 Jun; 438(2):206-16. PubMed ID: 15907782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of topoisomerase II alpha and beta in HIV-1 infected and uninfected neuroblastoma and astrocytoma cells: involvement of distinct nordihydroguaretic acid sensitive inflammatory pathways.
    Mandraju RK; Kondapi AK
    Arch Biochem Biophys; 2007 May; 461(1):40-9. PubMed ID: 17391642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A biochemical analysis of topoisomerase II alpha and beta kinase activity found in HIV-1 infected cells and virus.
    Kondapi AK; Padmaja G; Satyanarayana N; Mukhopadyaya R; Reitz MS
    Arch Biochem Biophys; 2005 Sep; 441(1):41-55. PubMed ID: 16091284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
    Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
    Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
    Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
    Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo.
    Linka RM; Porter AC; Volkov A; Mielke C; Boege F; Christensen MO
    Nucleic Acids Res; 2007; 35(11):3810-22. PubMed ID: 17526531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topoisomerase II poisoning and antineoplastic action by DNA-nonbinding diacetyl and dicarboxaldoxime derivatives of ferrocene.
    Vashisht Gopal YN; Jayaraju D; Kondapi AK
    Arch Biochem Biophys; 2000 Apr; 376(1):229-35. PubMed ID: 10729210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional compatibility between isoform alpha and beta of type II DNA topoisomerase.
    Sakaguchi A; Kikuchi A
    J Cell Sci; 2004 Mar; 117(Pt 7):1047-54. PubMed ID: 14996935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerase IIalpha inhibition following DNA transfection greatly enhances random integration in a human pre-B lymphocyte cell line.
    Toyoda E; Kurosawa A; Kamekawa H; Adachi N
    Biochem Biophys Res Commun; 2009 May; 382(3):492-6. PubMed ID: 19285952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity.
    Qiu J; Catapano CV; Fernandes DJ
    Biochemistry; 1996 Dec; 35(50):16354-60. PubMed ID: 8973211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
    Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
    Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of DNA topoisomerase II alpha/beta heterodimers in HeLa cells.
    Gromova I; Biersack H; Jensen S; Nielsen OF; Westergaard O; Andersen AH
    Biochemistry; 1998 Nov; 37(47):16645-52. PubMed ID: 9843432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of topoisomerases II alpha and beta in Chinese hamster lung cells resistant to topoisomerase II inhibitors.
    Khélifa T; Casabianca-Pignède MR; René B; Jacquemin-Sablon A
    Mol Pharmacol; 1994 Aug; 46(2):323-8. PubMed ID: 8078494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human topoisomerase I promotes HIV-1 proviral DNA synthesis: implications for the species specificity and cellular tropism of HIV-1 infection.
    Shoya Y; Tokunaga K; Sawa H; Maeda M; Ueno T; Yoshikawa T; Hasegawa H; Sata T; Kurata T; Hall WW; Cullen BR; Takahashi H
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8442-7. PubMed ID: 12829794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.
    Emmons M; Boulware D; Sullivan DM; Hazlehurst LA
    Biochem Pharmacol; 2006 Jun; 72(1):11-8. PubMed ID: 16678798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hairpin structures formed by alpha satellite DNA of human centromeres are cleaved by human topoisomerase IIalpha.
    Jonstrup AT; Thomsen T; Wang Y; Knudsen BR; Koch J; Andersen AH
    Nucleic Acids Res; 2008 Nov; 36(19):6165-74. PubMed ID: 18824478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense-mediated repression of DNA topoisomerase II expression leads to an impairment of HIV-1 replicative cycle.
    Bouillé P; Subra F; Mouscadet JF; Auclair C
    J Mol Biol; 1999 Jan; 285(3):945-54. PubMed ID: 9887261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiol-modulated mechanisms of the cytotoxicity of thimerosal and inhibition of DNA topoisomerase II alpha.
    Wu X; Liang H; O'Hara KA; Yalowich JC; Hasinoff BB
    Chem Res Toxicol; 2008 Feb; 21(2):483-93. PubMed ID: 18197631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
    Finlay GJ; Atwell GJ; Baguley BC
    Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.